Company Overview - Atara Biotherapeutics (ATRA) shares increased by 10% to close at $14.26, with notable trading volume compared to typical sessions, and a 2.6% gain over the past four weeks [1][2] Product Development - The rise in stock price is linked to growing investor optimism regarding Atara's lead product candidate, tabelecleucel (tab-cel), a T-cell immunotherapy for Epstein-Barr virus-positive post-transplant lymphoproliferative disease (EBV+ PTLD) [2] - Atara has resubmitted its biologics license application for tab-cel, which is currently under priority review by the FDA, with a decision expected on January 10, 2026 [2] Financial Performance - Atara is projected to report a quarterly loss of $0.83 per share, reflecting a year-over-year increase of 71.7%, while revenues are expected to be $1.29 million, down 96.8% from the same quarter last year [3] - The consensus EPS estimate for Atara has remained unchanged over the last 30 days, indicating that stock price movements may not sustain without trends in earnings estimate revisions [4] Industry Context - Atara Biotherapeutics is part of the Zacks Medical - Biomedical and Genetics industry, which includes Amicus Therapeutics (FOLD), another stock in the same sector that closed 2.3% higher at $8.35 and has returned 8.5% over the past month [5] - Amicus Therapeutics has a consensus EPS estimate of $0.12 for its upcoming report, representing a year-over-year change of 20%, and also holds a Zacks Rank of 3 (Hold) [6]

Core Insights - Atara Biotherapeutics, Inc. is a biotechnology company focused on immunotherapy for serious diseases, distinguishing itself with innovative approaches and strong financial metrics [1] Financial Performance - Atara's Return on Invested Capital (ROIC) is 36.19%, significantly higher than its Weighted Average Cost of Capital (WACC) of 6.53%, resulting in a ROIC to WACC ratio of 5.54, indicating effective capital utilization and strong potential for value creation [2][6] - In contrast, G1 Therapeutics, Inc. has a negative ROIC of -17.42% and a WACC of 12.24%, leading to a ROIC to WACC ratio of -1.42, highlighting inefficiencies in capital use [3] - Allogene Therapeutics, Inc. shows a ROIC of -57.03% against a WACC of 4.85%, resulting in a ROIC to WACC ratio of -11.77, further emphasizing capital inefficiency [3] - MacroGenics, Inc. and AnaptysBio, Inc. exhibit negative ROIC to WACC ratios of -3.98 and -2.27, respectively, indicating challenges in capital management [4] - CytomX Therapeutics, Inc. has a ROIC of 30.37% and a WACC of 13.35%, resulting in a ROIC to WACC ratio of 2.27, which, while positive, is less efficient than Atara [5][6] Competitive Landscape - Atara Biotherapeutics leads its peers in capital efficiency within the biotechnology sector, showcasing a strong position compared to competitors with negative or lower ROIC to WACC ratios [5][6]

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q | Title of Each Class | Trading Symbol(s) | Name of Each Exchange on Which Registered | | --- | --- | --- | | Common Stock, par value $0.0001 per share | ATRA | The Nasdaq Stock Market LLC | ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2025 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the tr ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 14, 2025 Atara Biotherapeutics, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-36548 46-0920988 (State or Other Jurisdiction of Incorporation) (Commission File Number) (IRS Employer Identification No.) 2380 Conejo Spectrum Street Suite 200 Thousand Oaks, Californi ...

First allogeneic T-Cell therapy BLA offers hope to EBV+ PTLD patients who have limited treatment options and lifespan measured in only a few weeks to months following failure of initial treatmentEBV+ PTLD is an ultra-rare, acute, and potentially deadly blood malignancy that occurs after hematopoietic cell transplant (HCT) or solid organ transplant (SOT) when T-cell activity is impaired by immunosuppressionTabelecleucel has a Prescription Drug User Fee Act (PDUFA) target action date of January 10, 2026 and w ...

Atara Biotherapeutics resubmitted the tabelecleucel Biologics License Application (BLA) to the U.S. Food and Drug Administration on July 11 Pierre Fabre Laboratories is now responsible for all global clinical trial activities for the tabelecleucel clinical program Enrollment is ongoing for pivotal, Phase 3 ALLELE Study (NCT03394365) investigating tabelecleucel in patients with EBV+PTLD in Solid Organ Transplant and Allogeneic Hematopoietic Cell Transplant after failure of standard therapy NCT04554914 also o ...

Financial Data and Key Metrics Changes - The meeting reported that proxies were received for approximately 76% of the total outstanding shares, indicating a strong shareholder engagement [8] - The preliminary results showed that all proposals were approved, including the election of directors and the advisory vote on executive compensation [11][12] Business Line Data and Key Metrics Changes - No specific business line data or key metrics were discussed during the meeting [10] Market Data and Key Metrics Changes - No specific market data or key metrics were provided during the meeting [10] Company Strategy and Development Direction and Industry Competition - The company is focused on maintaining strong governance through the election of directors and the advisory vote on executive compensation, reflecting a commitment to shareholder interests [9][12] Management's Comments on Operating Environment and Future Outlook - Management did not provide specific comments on the operating environment or future outlook during the meeting [10] Other Important Information - The meeting was conducted virtually, and all voting was completed online, ensuring accessibility for shareholders [3][5] - The results of the voting will be published in a current report on Form 8-K within four business days [12] Q&A Session Summary - There were no questions submitted during the Q&A session [10]

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 For the transition period from to Commission file number 001-36548 ATARA BIOTHERAPEUTICS, INC. (Exact Name of Registrant as Specified in its Charter) | Delaware | 46-0920988 | | --- | --- | | (State or Other Jurisdiction of Incorporation or Organization) | (I.R.S. Employer Identification No.) | | 1280 Rancho Conejo Boulevard | | | Thousand Oaks, CA | 91320 | | (Address of Principal Executive Offices) | (Zip Code) | | Registrant's Teleph ...

[Q1 2025 Financial Results and Operational Progress](index=1&type=section&id=Atara%20Biotherapeutics%20Announces%20First%20Quarter%20Financial%20Results%20and%20Operational%20Progress) The company secured new financing and implemented major cost reductions to extend its cash runway while focusing resources on its lead program, tab-cel - Atara secured **$16 million in financing**, which is expected to extend its cash runway through the first quarter of 2026[2](index=2&type=chunk)[7](index=7&type=chunk)[13](index=13&type=chunk) - The company is implementing significant cost reductions, including workforce and program cuts, and expects to **reduce operating expenses by approximately 65%** year-over-year in 2025[1](index=1&type=chunk)[6](index=6&type=chunk)[13](index=13&type=chunk) - All manufacturing responsibilities and costs for its lead candidate, tabelecleucel, have been **transferred to partner Pierre Fabre Laboratories**[1](index=1&type=chunk)[4](index=4&type=chunk) - Development of the company's CAR T programs (ATA3219 and ATA3431) has been **discontinued to focus resources on tabelecleucel**[3](index=3&type=chunk) [Operational Highlights & Pipeline Update](index=1&type=section&id=Operational%20Highlights%20%26%20Pipeline%20Update) Atara is advancing tab-cel® by addressing FDA feedback and transferring manufacturing, while discontinuing CAR T programs to conserve resources [Tabelecleucel (tab-cel® or EbvalloTM)](index=1&type=section&id=Tabelecleucel%20(tab-cel%C2%AE%20or%20EbvalloTM)%20for%20Post-Transplant%20Lymphoproliferative%20Disease%20(PTLD)) The company is actively working with the FDA to advance its lead program, tab-cel®, towards a Biologics License Application resubmission - The FDA has **lifted the clinical holds** on EBVALLOTM studies, and Atara plans to resume enrollment in its Phase 3 and Phase 2 studies[4](index=4&type=chunk) - A **Type A meeting with the FDA is scheduled for Q2 2025** to discuss the path for resubmitting the EBVALLOTM Biologics License Application (BLA)[4](index=4&type=chunk) - As of March 2025, all worldwide **manufacturing responsibility for tab-cel has been transferred** to partner Pierre Fabre Laboratories[4](index=4&type=chunk) - Atara remains eligible for **significant milestone payments and royalties** from Pierre Fabre upon potential FDA approval and commercial sales of EBVALLOTM[4](index=4&type=chunk) [CAR T Programs](index=1&type=section&id=CAR%20T%20Programs%20Discontinued) Development of the company's CAR T programs has been paused to prioritize resources for its lead asset - Atara has **paused the development of its CAR T programs** (ATA3219 and ATA3431), with wind-down activities expected to be completed in the second quarter of 2025[3](index=3&type=chunk) [Corporate and Financial Updates](index=2&type=section&id=Corporate%20and%20Financial%20Updates) The company executed a strategic restructuring and secured new financing, resulting in a significant Q1 2025 revenue increase and a return to profitability [Corporate Updates](index=2&type=section&id=Corporate%20Updates) The company undertook a major restructuring, including workforce reductions and new financing, to strengthen its financial position - In May 2025, Atara implemented a strategic restructuring that resulted in a **30% workforce reduction**, retaining approximately 23 essential personnel[6](index=6&type=chunk) - The company entered into an underwriting agreement for an offering with expected **gross proceeds of $16 million** to fund activities towards tab-cel BLA approval and for general corporate purposes[7](index=7&type=chunk) - Atara has **paused its review of strategic options**, such as a merger or sale, pending the outcome of the Type A meeting with the FDA scheduled for Q2 2025[5](index=5&type=chunk) [First Quarter 2025 Financial Results](index=2&type=section&id=First%20Quarter%202025%20Financial%20Results) Q1 2025 saw a dramatic revenue increase and a shift to net income, driven by the Pierre Fabre agreement Q1 2025 Financial Highlights | Financial Metric | Q1 2025 | Q1 2024 | Change (YoY) | | :--- | :--- | :--- | :--- | | Total Revenues | $98.1M | $27.4M | +$70.7M | | R&D Expenses | $27.4M | $45.5M | -$18.1M | | G&A Expenses | $11.5M | $11.1M | +$0.4M | | Net Income (Loss) | $38.0M | $(31.8)M | +$69.8M | | Diluted EPS | $3.50 | $(5.65) | +$9.15 | - The significant increase in total revenues was primarily due to **revenue recognized from the Pierre Fabre agreement** following the transfer of manufacturing responsibilities[8](index=8&type=chunk) - Cash, cash equivalents, and short-term investments totaled **$13.8 million** as of March 31, 2025, compared to $42.5 million as of December 31, 2024[8](index=8&type=chunk) [2025 Outlook and Cash Runway](index=3&type=section&id=2025%20Outlook%20and%20Cash%20Runway) Atara projects a 65% reduction in 2025 operating expenses and has extended its cash runway into Q1 2026 with recent financing - The company projects that its cash position as of March 31, 2025, combined with the **$16M gross proceeds** from the May 2025 offering, will fund planned operations into the first quarter of 2026[13](index=13&type=chunk) - Full-year 2025 operating expenses are expected to **decrease by approximately 65%** from 2024, with the largest reduction anticipated in Q2 2025[1](index=1&type=chunk)[13](index=13&type=chunk) - The company has **reduced its headcount by approximately 85%** since December 31, 2024, as part of its cost reduction initiatives[13](index=13&type=chunk) [Financial Statements](index=4&type=section&id=Financial%20Statements) This section provides the unaudited Consolidated Balance Sheets and Statements of Operations as of and for the period ended March 31, 2025 [Consolidated Balance Sheets](index=4&type=section&id=Consolidated%20Balance%20Sheets) The balance sheet reflects a decrease in total assets and a significant reduction in liabilities, primarily from deferred revenue recognition Consolidated Balance Sheet Summary | Balance Sheet Item (In thousands) | March 31, 2025 | December 31, 2024 | | :--- | :--- | :--- | | **Assets** | | | | Cash and cash equivalents | $13,841 | $25,030 | | Total current assets | $27,182 | $64,894 | | **Total assets** | **$62,038** | **$109,098** | | **Liabilities & Equity** | | | | Deferred revenue (current) | $15,983 | $95,092 | | Total current liabilities | $47,892 | $134,574 | | **Total liabilities** | **$117,110** | **$206,381** | | **Total stockholders' (deficit) equity** | **$(55,072)** | **$(97,283)** | - Total assets decreased to **$62.0 million** as of March 31, 2025, from $109.1 million at December 31, 2024[15](index=15&type=chunk) - Total liabilities decreased significantly to **$117.1 million** from $206.4 million, primarily due to a reduction in deferred revenue from $95.1 million to $16.0 million[15](index=15&type=chunk) [Consolidated Statements of Operations](index=5&type=section&id=Consolidated%20Statements%20of%20Operations%20and%20Comprehensive%20Loss) The company achieved a significant net income of $38.0 million in Q1 2025, a stark contrast to the net loss in the prior-year period Consolidated Statement of Operations Summary | Statement of Operations (In thousands) | Three Months Ended March 31, 2025 | Three Months Ended March 31, 2024 | | :--- | :--- | :--- | | Commercialization revenue | $98,149 | $27,357 | | Total costs and operating expenses | $59,347 | $58,604 | | Income (loss) from operations | $38,802 | $(31,247) | | **Net income (loss)** | **$38,010** | **$(31,752)** | - The company reported a **net income of $38.0 million** for Q1 2025, a significant turnaround from a net loss of $31.8 million in Q1 2024[9](index=9&type=chunk)[17](index=17&type=chunk) - Diluted net income per common share was **$3.50 for Q1 2025**, compared to a diluted net loss per share of $5.65 in the same period of 2024[9](index=9&type=chunk)[17](index=17&type=chunk)

Core Viewpoint - Atara Biotherapeutics (ATRA) has been upgraded to a Zacks Rank 2 (Buy), indicating a positive outlook driven by rising earnings estimates, which significantly influence stock prices [1][3]. Earnings Estimates and Stock Price Impact - The Zacks rating system emphasizes the importance of earnings estimate revisions, which are strongly correlated with near-term stock price movements [4][6]. - Institutional investors often adjust their valuations based on changes in earnings estimates, leading to significant buying or selling actions that affect stock prices [4]. Company Performance and Outlook - Atara Biotherapeutics is projected to report earnings of -$5.94 per share for the fiscal year ending December 2025, reflecting a year-over-year change of 47.9% [8]. - Over the past three months, the Zacks Consensus Estimate for Atara has increased by 55%, indicating a positive trend in earnings expectations [8][10]. Zacks Rating System - The Zacks Rank system classifies stocks into five groups based on earnings estimates, with only the top 20% receiving a 'Strong Buy' or 'Buy' rating, suggesting superior potential for market-beating returns [9][10]. - The upgrade of Atara Biotherapeutics to Zacks Rank 2 places it in the top 20% of Zacks-covered stocks, indicating a strong likelihood of price appreciation in the near term [10].